Dr. Reddy's Laboratories Limited has informed the Exchange regarding a press release dated October 07, 2026, titled "Intimation of Earnings call".
Filed with NSE · ISIN INE089A01023 · · 2 pages · English
Summary by 6ix AI
Dr. Reddy's Laboratories Ltd. has announced an upcoming earnings call regarding its financial results for the second quarter of the fiscal year. The results will be released after a board meeting on a specified date, with the earnings call scheduled for the evening of the same day.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Dr. Reddy's Laboratories Ltd. on 6ix
Earlier from Dr. Reddy's Laboratories
- Dr. Reddy’s Announces the First-to-Market Launch of Sugammadex Injection 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials, a Generic Equivalent of Bridion®, in the United States
- Dr. Reddy's Laboratories Ltd. Press Release Aug 01 2026
- Dr. Reddy's Laboratories Ltd. Press Release Jul 23 2026
- Dr. Reddy's Laboratories Ltd. Press Release Jul 13 2026
- Dr. Reddy's Laboratories Limited Announces Filing of Annual Report on Form 20-F
Later from Dr. Reddy's Laboratories
- Dr. Reddy's Laboratories Limited has informed the Exchange regarding a press release dated October 21, 2026, titled "Dr. Reddy s Receives DCGI Approval for Zytorvi® (toripalimab) in Advanced Esophageal Squamous Cell Carcinoma, Its Second Approved Indication in India.".
- Dr. Reddy's Laboratories Limited has informed the Exchange regarding a press release dated November 05, 2026, titled "Dr. Reddy s receives marketing authorization for generic semaglutide injection in Brazil".
Follow Dr. Reddy's Laboratories into a list and get an email when it puts out news.
Follow Dr. Reddy's Laboratories